Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course Ceftriaxone in Severe Nontyphoidal Salmonella Enterocolitis
NCT01278017Phase 4Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Aug 2010
- Primary completion
- Jun 2011
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ceftriaxone in salmonellosis (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoints: Duration of clinical course of severe NTS enterocolitis at 3 months and Excretion of Salmonella in feces at 3 months. Status: unknown.
02
Drugs
ceftriaxone
03
Conditions
salmonellosis
Beyond the preview
Go deeper on NCT01278017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01278017.